Fig. 1From: Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centersCompliance of clinicians with the PREEMPT paradigm for Onabotulinumtoxin A (OBT-A) administration: a frequency of use of PREEMPT paradigm; b proportion of patients treated with the follow-the-pain paradigmBack to article page